Sabizabulin is an investigational new drug that is being evaluated for the treatment of castration-resistant prostate cancer[4] and in SARS-CoV-2 (COVID-19) infections.[5] It is a tubulin polymerization inhibitor.[6][7]
Clinical data | |
---|---|
Other names | VERU-111[1][2][3] |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C21H19N3O4 |
Molar mass | 377.400 g·mol−1 |
3D model (JSmol) | |
| |
|
Sabizabulin is chemical compound from the group of indole and imidazole derivatives that was first reported in 2012 by Dalton, Li, and Miller.[8]
Pharmacology
editPharmacokinetics
editSabizabulin is not a substrate of P-glycoprotein (Pgp), an efflux pump that, when overexpressed, can confer resistance to taxanes, a group of widely used cancer therapeutics.
Mechanism of action
editSabizabulin, as an orally available molecule, acts on microtubules, a component of the cytoskeleton. It binds to the colchicine binding site on the beta subunit of tubulin, as well as a novel site on the alpha subunit, and causes both to crosslink, thus depolymerizing microtubules and preventing their polymerization.[9] By preventing mitotic spindle formation, this directly inhibits mitosis of tumor cells and endothelial cells attempting to form new blood vessels to feed them. In parallel, microtubule-mediated trafficking of cellular components (including androgen receptors into the nucleus), thus, a potential anti-androgen agent. The transport of viral particles (including SARS-CoV-2) may also be inhibited. These activities can inhibit viral replication and assembly. Inhibition of tubulin polymerization can also inhibit the release of pro-inflammatory cytokines and disrupt the activities of inflammatory cells.[10]
Research
editCOVID-19 therapy
editIn a phase III study on the treatment of severe courses of COVID-19,[3][11] sabizabulin reduced mortality by 55% according to the manufacturer.[12] Because of the high efficacy, the test phase was stopped prematurely so that the drug no longer had to be withheld from the placebo control group.[13][14][medical citation needed]
References
edit- ^ "Substance Name: Sabizabulin". ChemIDplus. Retrieved 1 May 2022.
- ^ "Sabizabulin for COVID-19". Veru Inc. 14 January 2022. Retrieved 1 May 2022.
- ^ a b "VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study". ClinicalTrials.gov (Press release). 13 April 2021. Retrieved 1 May 2022.
- ^ Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, et al. (July 2022). "A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent". Clinical Cancer Research. 28 (13): 2789–2795. doi:10.1158/1078-0432.CCR-22-0162. PMC 9774054. PMID 35416959. S2CID 248128050.
- ^ rme (13 April 2022). "COVID-19: Krebsmittel Sabizabulin halbiert Sterberate bei schweren Erkrankungen" [COVID-19: Cancer drug Sabizabulin halves death rate in severe cases]. aerzteblatt.de. Retrieved 14 April 2022.
- ^ "Sabizabulin - Veru Healthcare". AdisInsight. Springer Nature Switzerland AG.
- ^ Mahmud F, Deng S, Chen H, Miller DD, Li W (December 2020). "Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer". Cancer Letters. 495: 76–88. doi:10.1016/j.canlet.2020.09.004. PMC 7669640. PMID 32920198.
- ^ Li CM, Lu Y, Chen J, Costello TA, Narayanan R, Dalton MN, et al. (November 2012). "Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer". Pharmaceutical Research. 29 (11): 3053–3063. doi:10.1007/s11095-012-0814-5. PMC 3646298. PMID 22760659.
- ^ "Sabizabulin for Breast Cancer". Veru Inc. Retrieved 17 May 2022.
- ^ "Sabizabulin". NCI Thesaurus. U.S. National Cancer Institute. Code C158517. Retrieved 14 April 2022.
- ^ "Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients". Veru Inc. 19 May 2021. Archived from the original on 1 May 2022. Retrieved 1 May 2022.
- ^ "Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy". Veru Inc. (Press release). 11 April 2022. Archived from the original on 16 April 2022. Retrieved 30 April 2022.
- ^ Rabin R (11 April 2022). "New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claims". The New York Times. Retrieved 21 April 2022.
- ^ "Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases" (Press release). Veru Inc. 25 April 2022. Retrieved 30 April 2022 – via GlobeNewswire.
Further reading
edit- Deng S, Krutilina RI, Wang Q, Lin Z, Parke DN, Playa HC, et al. (February 2020). "An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance". Molecular Cancer Therapeutics. 19 (2): 348–363. doi:10.1158/1535-7163.MCT-19-0536. PMC 7007836. PMID 31645441.
- Shahnoor S, Khan AM, Habiba U (June 2023). "Sabizabulin - an unprecedented yet effective drug against COVID-19". JPMA. The Journal of the Pakistan Medical Association. 73 (6): 1363. doi:10.47391/JPMA.7539. PMID 37427659.